Creso to tap emerging Canadian medicinal cannabis market
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Leading medicinal cannabis player, Creso Pharma Limited (ASX:CPH), today updated the market with a cluster of encouraging developments.
CPH has successfully completed due diligence for the Mernova Medicinal Inc. acquisition, a 20,000 square foot medical cannabis growing facility in Nova Scotia, Canada.
This development is tightly aligned with a shifting legislative climate – and subsequently emerging market – in Canada.
CPH has also advised that the application for a medical cannabis cultivation licence under Health Canada’s Access to Cannabis for Medical Purposes Regulation (ACMPR) program is progressing.
This will give CPH a considerable competitive advantage as the only ASX-listed medicinal cannabis company with 100% ownership and capacity to cultivate, extract and manufacture its own innovative cannabis and hemp-derived human and animal therapeutic products in Canada – not to mention one of the few such companies globally.
These products will be available for local distribution, as well as export to countries which accept cannabis and hemp imports.
Market penetration is yet to be seen so investors should seek professional financial advice for further information if considering this stock for their portfolio.
CPH has also announced that a construction contract has been signed with Avondale Construction Ltd, and completion of the new production facility is strategically targeted to coincide with the July 2018 legalisation of recreational cannabis in Canada.
Once completed, the 20,000 square foot facility is expected to produce 2,000-4,000 kilograms of cannabis per year.
CPH and Mernova have also agreed to exercise the right of first refusal option on the adjoining land parcel, allowing Mernova in time to expand the facility to up to 200,000 square feet. The total land purchased is 9.75 acres.
The current facility will be built in a way that is scalable and which can grow alongside demand with the emergence of the recreational market.
The facility is currently being built and will be operated to GACP and GPP (GMP) standards, ensuring it can expand research and development capability for CPH.
Also highly promising is that Canada is amending the Cannabis Act. Bill C-45 to allow sale of edible medicinal cannabis products in 2019.
This opens a fertile market for CPH’s cannaQIX® and cannapeal® product ranges. These are hemp-based nutraceutical products created using proprietary innovative delivery technologies. These have been authorised to market, with Free Sales Certificates for global export in full compliance with Federal Swiss Food Laws and Regulations.
The introduction of these product ranges into the anxiety and stress treatment space is backed by strong scientific rationale.
The Canadian market is clearly flourishing. As of June, over 200,000 patients are now registered for medicinal cannabis in Canada (as opposed to last year’s 75,000).
The Canadian government intends to bring the proposed Cannabis Act into force no later than July 2018.
Nova Scotia has opened public consultation so it can take responsibility for developing, implementing, maintaining and enforcing systems to oversee the distribution and retail sale of cannabis, in close collaboration with municipalities.
The proposed Cannabis Act will allow Nova Scotia to license and oversee the distribution and sale of cannabis, subject to federal conditions.
CPH and Mernova join 16 other licenced producers to develop guidelines relating to how the drug should be branded and promoted before its recreational use becomes legal next year. These industry leaders have enlisted the help of Advertising Standards Canada. Interestingly, the guidelines developed here could serve as a baseline for the government’s consultations.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
